Table 3.
Assessment of the timed function/second of the studied group of patients pre- and at the end of 6-month prednisone therapy
| DMD Range (Mean ± SD) | BMD Range (Mean ± SD) | LGMD Range (Mean ± SD) | ||||
|---|---|---|---|---|---|---|
| Timed function/ second and Overall disability | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment |
| Timed function/second | 8.9 ± 2.5 | 6.1 ± 2.3*** | 7.3 ± 0.8 | 4.8 ± 1.2*** | 7.6 ± 2.5 | 8.4 ± 2.9 |
| Time in seconds (Mean ± SD) to rise upfrom the ground to standing position 2 to <14 s | ||||||
| Time in seconds (Mean ± SD) for going up 9 stairs; 4 to <31 s | 14.9 ± 5.8 | 10.1 ± 4.7*** | 10.2 ± 1.9 | 6.9 ± 1.6*** | 15.4 ± 8.7 | 16.1 ± 8.0 |
| Time in seconds to travel 10 meters as rapidas possible; 4 to <22 s | 10.7 ± 3.4 | 7.7 ± 2.5*** | 9.2 ± 2.7 | 5.5 ± 2.1** | 12.1 ± 7.7 | 13.3 ± 8.8 |
| Overall disability | ||||||
| In upper limbs | 5.7 ± 0.6 | 6.4 ± 0.7*** | 5.8 ± 0.4 | 6.7 ± 0.5** | 6.0 ± 1.0 | 5.9 ± 1.5 |
| In lower limbs | 8.2 ± 1.5 | 9.4 ± 1.3*** | 9.0 ± 0.0 | 9.7 ± 0.5* | 8.9 ± 0.7 | 8.7 ± 1.0 |
BMD, Becker muscular dystrophies; DMD, Duchenne muscular dystrophies; LGMD, limb girdle muscular dystrophies.
*
P < 0.05
**
P < 0.01
***
P < 0.001.